Literature DB >> 35534547

RUNX2 recruits the NuRD(MTA1)/CRL4B complex to promote breast cancer progression and bone metastasis.

Xin Yin1, Xu Teng1, Tianyu Ma2, Tianshu Yang1, Jingyao Zhang2, Miaomiao Huo2, Wei Liu3, Yunkai Yang2, Baowen Yuan2, Hefen Yu1, Wei Huang4, Yan Wang5.   

Abstract

Runt-related transcription factor 2 (RUNX2) is an osteogenesis-related transcription factor that has emerged as a prominent transcription repressing factor in carcinogenesis. However, the role of RUNX2 in breast cancer metastasis remains poorly understood. Here, we show that RUNX2 recruits the metastasis-associated 1 (MTA1)/NuRD and the Cullin 4B (CUL4B)-Ring E3 ligase (CRL4B) complex to form a transcriptional-repressive complex, which catalyzes the histone deacetylation and ubiquitylation. Genome-wide analysis of the RUNX2/NuRD(MTA1)/CRL4B complex targets identified a cohort of genes including peroxisome proliferator-activated receptor alpha (PPARα) and superoxide dismutase 2 (SOD2), which are critically involved in cell growth, epithelial-to-mesenchymal transition (EMT) and invasion. We demonstrate that the RUNX2/NuRD(MTA1)/CRL4B complex promotes the proliferation, invasion, tumorigenesis, bone metastasis, cancer stemness of breast cancer in vitro and in vivo. Strikingly, RUNX2 expression is upregulated in multiple human carcinomas, including breast cancer. Our study suggests that RUNX2 is a promising potential target for the future treatment strategies of breast cancer.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 35534547     DOI: 10.1038/s41418-022-01010-2

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  39 in total

1.  Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.

Authors:  Kyle C Kurek; Sara Del Mare; Zaidoun Salah; Suhaib Abdeen; Hussain Sadiq; Suk-Hee Lee; Eugenio Gaudio; Nicola Zanesi; Kevin B Jones; Barry DeYoung; Gail Amir; Mark Gebhardt; Matthew Warman; Gary S Stein; Janet L Stein; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets.

Authors:  Yiran Liang; Hanwen Zhang; Xiaojin Song; Qifeng Yang
Journal:  Semin Cancer Biol       Date:  2019-08-14       Impact factor: 15.707

3.  Multiscale characterization of the mineral phase at skeletal sites of breast cancer metastasis.

Authors:  Frank He; Aaron E Chiou; Hyun Chae Loh; Maureen Lynch; Bo Ri Seo; Young Hye Song; Min Joon Lee; Rebecca Hoerth; Emely L Bortel; Bettina M Willie; Georg N Duda; Lara A Estroff; Admir Masic; Wolfgang Wagermaier; Peter Fratzl; Claudia Fischbach
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

4.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 5.  Bone Metastasis: Find Your Niche and Fit in.

Authors:  Weijie Zhang; Igor Bado; Hai Wang; Hin-Ching Lo; Xiang H-F Zhang
Journal:  Trends Cancer       Date:  2019-01-17

Review 6.  RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression.

Authors:  Karine A Cohen-Solal; Rajeev K Boregowda; Ahmed Lasfar
Journal:  Mol Cancer       Date:  2015-07-25       Impact factor: 27.401

7.  RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.

Authors:  Yang Bai; Yinhui Yang; Yuqian Yan; Jian Zhong; Alexandra M Blee; Yunqian Pan; Tao Ma; R Jeffrey Karnes; Rafael Jimenez; Wanhai Xu; Haojie Huang
Journal:  Theranostics       Date:  2019-05-24       Impact factor: 11.556

8.  SET7/9 promotes multiple malignant processes in breast cancer development via RUNX2 activation and is negatively regulated by TRIM21.

Authors:  Wenzhe Si; Jiansuo Zhou; Yang Zhao; Jiajia Zheng; Liyan Cui
Journal:  Cell Death Dis       Date:  2020-02-26       Impact factor: 8.469

9.  Runx2 is a novel regulator of mammary epithelial cell fate in development and breast cancer.

Authors:  Thomas W Owens; Renee L Rogers; Sarah Best; Anita Ledger; Anne-Marie Mooney; Alison Ferguson; Paul Shore; Alexander Swarbrick; Christopher J Ormandy; Peter T Simpson; Jason S Carroll; Jane Visvader; Matthew J Naylor
Journal:  Cancer Res       Date:  2014-07-23       Impact factor: 12.701

Review 10.  The Roles of Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Breast Cancer Bone Metastasis: Potential Targets for Prevention and Treatment.

Authors:  Binnaz Demirkan
Journal:  J Clin Med       Date:  2013-11-22       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.